摘要
William Dameshek（1951）提出骨髓增殖性肿瘤（myeloproliferative neoplasms,MPNs）的概念,认为真性红细胞增多症（PV）、原发性血小板增多症（ET）、原发性骨髓纤维化（PMF）属于同一组疾病。Kralovics等（2005）对JAK2 V617F突变在MPNs患者中的发现,更加印证了上述概念提出的重要意义。随后在少数ET和PMF患者中发现MPL突变。2013年,有研究在JAK2、MPL基因突变阴性的ET和MF患者中,
The last decade has witnessed tremendous scientific advances,ushered in by the JAK2V617Fdiscovery,contributing to enhanced diagnostic capability and understanding of the biology of myeloproliferative neoplasms（MPNs）.Discovery of the calreticulin mutations filled a diagnostic gap.More recent work sheds light on molecular contribution to disease pathogenesis and prognosis.This article reviews the advances in molecular studies and its clinical value in MPNs.
出处
《临床血液学杂志》
CAS
2017年第6期887-891,共5页
Journal of Clinical Hematology
关键词
骨髓增殖性肿瘤
发病机制
预后
治疗
myeloproliferative neoplasm
pathogenesis
prognosis
therapy
